Solna, Sweden, March 17: One-carbon Therapeutics, a clinical-stage oncology company pioneering first-in-class targeted therapies based on deep understanding into cancer biology, today announced a strategic collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine. The collaboration will leverage Tempus’ proprietary, de-identified multimodal database and bioinformatics expertise to advance molecular insights supporting the clinical development of TH9619.
Through this collaboration, One-carbon Therapeutics will utilize Tempus’ analytical services to characterize the expression landscape across prioritized solid tumor indications. By integrating RNA sequencing data with clinical variables, the teams aim to uncover deep molecular insights that will inform the development of TH9619.
“Understanding the molecular dynamics of one-carbon metabolism across tumor types and treatment settings is fundamental to advancing TH9619 with precision,” said Ana Slipicevic, Chief Executive Officer at One-carbon Therapeutics. “Tempus’ depth of molecular data and analytical rigor enables us to generate statistically robust evidence that can potentially guide clinical decision making and optimize development.”
“At Tempus, our goal is to accelerate progress in oncology by translating complex molecular insights into meaningful therapeutic advances,” said Ezra Cohen, MD, Chief Medical Officer, Oncology, at Tempus. “Through comprehensive analysis of our multimodal dataset, we are supporting One-carbon Therapeutics in characterizing the metabolic signatures across diverse tumor types. These insights are essential to informing research strategies and advancing the development of next-generation targeted cancer therapies.”
By deepening the understanding of the biological mechanisms and genetic profiles associated with one-carbon metabolism across tumor types, the collaboration will strengthen the precision-driven clinical strategy for TH9619. Building on a deep understanding of how cancer cells depend on this pathway, these analyses may help identify patient populations most likely to benefit from treatment. This approach has the potential to enhance development efficiency, reduce uncertainty and ultimately help ensure that innovative targeted therapies reach the patients who need them most.
